Product Center
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-07-02
- Views:
(Summary description)Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.
(Summary description)Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-07-02 09:29
- Views:
Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. This makes it the world's first monkeypox mRNA vaccine to simultaneously obtain clinical trial approvals in both China and the United States. This milestone not only further validates the company's R&D capabilities but also strongly affirms the strength of Zhonghui Biotech's mRNA technology platform, demonstrating the company's solid capacity to contribute to global public health prevention and control efforts in China.

Regarding the monkeypox mRNA vaccine
This monkeypox mRNA vaccine employs an innovative quadrivalent antigen (A27, L1, A33, B5) tandem design with proprietary intellectual property rights, enabling independent expression of all four antigens on a single mRNA strand. In nonclinical studies, the vaccine demonstrated excellent immunogenicity (high levels of binding antibodies, neutralizing antibodies, and cellular immunity) and favorable safety profiles in both SD rats and rhesus macaque models, along with robust protective efficacy in monkeypox challenge trials. Regarding manufacturing processes, the product features high production capacity and stringent quality control, offering advantages for commercialization. It is poised to provide a safer and more effective next-generation solution for global monkeypox prevention and control efforts.
Regarding the mRNA technology platform
The monkeypox mRNA vaccine represents another innovative achievement of the company's mRNA technology platform. To date, two innovative vaccines developed using this platform have obtained dual clinical trial approvals in both China and the United States. The sustained delivery of such innovations is attributed to the mRNA technology platform established by the company's doctoral teams worldwide. The platform's core strengths lie in its rapid development capabilities and scalable production potential; as a "digital" platform, it enables swift design and synthesis once the target sequence is identified, facilitating rapid iteration. In terms of safety, mRNA does not enter the cell nucleus, eliminating the risk of genomic integration. Regarding efficacy, through sequence optimization and advanced delivery systems, it can simultaneously induce robust humoral and cellular immunity.
To date, the company has established comprehensive technical expertise in developing single-pathogen mRNA vaccines for infectious diseases and will rapidly expand its capabilities to include multi-pathogen combination vaccine development as well as innovative mRNA-based cancer therapies. Additionally, the company is actively leveraging AI technologies to enhance its mRNA technology platform, thereby improving research efficiency and quality.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us